DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation – A REPORT FROM the Ibfm-STUDY GROUP.
Libi Hertzberg(Tel Aviv University), Shai Izraeli(Tel Aviv University), Ithamar Ganmore(Tel Aviv University), Martin Stanulla(Leibniz University Hannover), Jane Chalker(Great Ormond Street Hospital), Geertruy te Kronnie(University of Padua), Elena Vendramini(University of Padua), Sabine Strehl(St Anna Children's Hospital), Chen Shochat(Bar-Ilan University), Lisa J Russel, Gunnar Cario, Beat Bornhäuser(University Children's Hospital Zurich), Arndt Borkardt(Heinrich Heine University Düsseldorf), Dani Bercovich(Tel Hai Academic College), Sharon Zeligson(Sheba Medical Center), Helena Kempski(Great Ormond Street Hospital), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Eytan Domany(Weizmann Institute of Science), Ilaria Iacobucci(St. Jude Children's Research Hospital), Akinori Yoda(Kyoto University), Gideon Rechavi(Tel Aviv University), Giovanni Cazzaniga(University of Milano-Bicocca), Christine J. Harrison(Newcastle University), Maike Schmitz(University of Zurich), Ruth Shiloh(Tel Aviv University)
Cited by 5
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627